Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The request follows a similar move by Eli Lilly, which has asked for a ban ... and effective" semaglutide products, adding: "These drugs are inherently complex to compound safely, and the risks ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

US stocks were mixed on Thursday in anticipation of Amazon's quarterly results, as investors assessed the earnings season so ...

Top Republican recipients of contributions from employees or PACS associated with the pharmaceutical/health products ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

The total market for glucagon products for hypoglycaemia has been estimated to be worth around $2 billion worldwide. Lilly acquired rights to Baqsimi from Canadian biotech Locemia Solutions in ...